Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition
Company

Viatris Posts Q3 2025 Revenue Dip, Highlights Emerging‑Market Branded Growth and Aculys Pharma Acquisition

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension
CompanyDrug

Humanwell Healthcare Secures NMPA Approval to Launch First Fixed‑Dose Combination for Pulmonary Arterial Hypertension

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
CompanyDrug

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China
Medical Device

Johnson & Johnson Launches ETHICON 4000 3D Laparoscopic Stapler in China

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum
Company

BeOne Medicines Posts $1.4 B Q3 2025 Revenue, Driven by BRUKINSA Momentum

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting
CompanyDrug

CStone Pharmaceuticals to Unveil CS2015 Data at 2025 ACAA​I Meeting

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal
CompanyDeals

AmacaThera Signs Exclusive Global License with Pacira BioSciences for AMT‑143, Up to $230 M Deal

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP
Others

Sanofi’s Cablivi Wins China NMPA Approval – First Nanobody Drug for aTTP

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera
Others

Judge Rejects Pfizer’s Attempt to Block Novo Nordisk’s $10 bn Bid for Metsera

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance
Company

Amgen Reports 12% YoY Sales Growth in Q3 2025, Raises Full‑Year Revenue Guidance

Eli Lilly & Novo Nordisk Reach U.S. Deal to Cut Obesity‑Drug Prices, Unlock Medicare & Medicaid Access
Company

AstraZeneca Posts 11% Y/Y Revenue Rise to $43.24 bn in First Nine‑Months of 2025

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks
Policy / Regulatory

NHSA Concludes 2025 National Basic Medical Insurance Drug Catalogue Negotiation and Commercial Insurance Innovative Drug Price Talks